Growth Hormone and Prader-Willi Syndrome

Aaron L. Carrel; Phillip D.K. Lee; Harriette R. Mogul

doi:10.1007/978-3-030-98171-6_7

Growth Hormone and Prader-Willi Syndrome

Aaron L. Carrel, Phillip D.K. Lee, Harriette R. Mogul

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

In 2000, biosynthetic growth hormone (GH) became the first medication to receive regulatory approval for treatment of PWS. As of this writing, biosynthetic GH (somatropin and somatropin biosimilars) continues to be the only approved medication for PWS, with published evidence demonstrating significant benefits for children and adults with PWS [1]. This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment efficacy and safety in PWS.

Original language	English (US)
Title of host publication	Management of Prader-Willi Syndrome
Subtitle of host publication	Fourth Edition
Publisher	Springer International Publishing
Pages	195-216
Number of pages	22
ISBN (Electronic)	9783030981716
ISBN (Print)	9783030981709
DOIs	https://doi.org/10.1007/978-3-030-98171-6_7
State	Published - Jan 1 2022
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-98171-6_7

Cite this

@inbook{e8233858365f469fa7f20b3441680936,

title = "Growth Hormone and Prader-Willi Syndrome",

abstract = "In 2000, biosynthetic growth hormone (GH) became the first medication to receive regulatory approval for treatment of PWS. As of this writing, biosynthetic GH (somatropin and somatropin biosimilars) continues to be the only approved medication for PWS, with published evidence demonstrating significant benefits for children and adults with PWS [1]. This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment efficacy and safety in PWS.",

author = "Carrel, {Aaron L.} and Lee, {Phillip D.K.} and Mogul, {Harriette R.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 1988, 1995, 2006, 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-030-98171-6_7",

language = "English (US)",

isbn = "9783030981709",

pages = "195--216",

booktitle = "Management of Prader-Willi Syndrome",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Growth Hormone and Prader-Willi Syndrome

AU - Carrel, Aaron L.

AU - Lee, Phillip D.K.

AU - Mogul, Harriette R.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 1988, 1995, 2006, 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - In 2000, biosynthetic growth hormone (GH) became the first medication to receive regulatory approval for treatment of PWS. As of this writing, biosynthetic GH (somatropin and somatropin biosimilars) continues to be the only approved medication for PWS, with published evidence demonstrating significant benefits for children and adults with PWS [1]. This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment efficacy and safety in PWS.

AB - In 2000, biosynthetic growth hormone (GH) became the first medication to receive regulatory approval for treatment of PWS. As of this writing, biosynthetic GH (somatropin and somatropin biosimilars) continues to be the only approved medication for PWS, with published evidence demonstrating significant benefits for children and adults with PWS [1]. This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment efficacy and safety in PWS.

UR - http://www.scopus.com/inward/record.url?scp=85158998135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85158998135&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-98171-6_7

DO - 10.1007/978-3-030-98171-6_7

M3 - Chapter

AN - SCOPUS:85158998135

SN - 9783030981709

SP - 195

EP - 216

BT - Management of Prader-Willi Syndrome

PB - Springer International Publishing

ER -

Growth Hormone and Prader-Willi Syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this